Effects of long-acting and short-acting β-agonists on methacholine dose-response curves in asthmatics

European Respiratory Journal

Volumn 10, Issue 2, 1997, Pages 330-336

  Wong, A G ^a   O'Shaughnessy, A D ^a   Walker, C M ^a   Sears, M R ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

agonists; airway responsiveness; asthma; dose response slope; salbutamol; salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; METHACHOLINE; SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED;

EID: 0031056035     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10020330     Document Type: Article

References (35)

1. Hargreave FE, Dolovich J, O'Byrne PM, Ramsdale EH, Daniel EE. The origin of airway hyperresponsiveness. J Allergy Clin Immunol 1986; 78: 825-832.
2. Holgate ST, Beasley R, Twentyman OP. The pathogenesis and significance of bronchial hyperresponsiveness in airways disease. Clin Sci 1987; 73: 561-572.
3. Woolcock AJ, Salome CM, Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. Am Rev Respir Dis 1984; 130: 71-75.
4. Sterk PJ, Bel EH. The shape of the dose-response curve to bronchoconstrictor agents in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1433-1437.
5. Cockcroft DW. Nonallergic airway responsiveness. J Allergy Clin Immunol 1988; 81: 111-119.
6. Sterk PJ, Timmers MC, Dijkman JH. Maximal airway narrowing in humans in vivo: histamine compared with methacholine. Am Rev Respir Dis 1986; 134: 714-718.
7. Sterk PJ, Daniel EE, Zamel N, Hargreave FE. Limited bronchoconstriction to methacholine using partial flow-volume curves in nonasthmatic subjects. Am Rev Respir Dis 1985; 132: 272-277.
8. Sterk PJ. The determinants of the severity of acute airway narrowing in asthma and COPD. Respir Med 1992; 86: 391-396.
9. Tattersfield AE. Effect of beta-agonists and anticholinergic drugs on bronchial reactivity. Am Rev Respir Dis 1987; 136(Suppl. 4): S64-S68.
10. 2-agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 1991; 46: 9-14.
11. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
12. 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991; 104: 665-671.
13. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990; 142: 571-575.
14. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198-1203.
15. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1992; 88: 363-368.
16. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993; 87: 227-228.
17. Dantzker DR, Pingleton SK, Pierce JA, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
18. Cockcroft DW, Killian DN, Mellon JA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235-243.
19. Finkelstein FN. Risks of salmeterol? N Engl J Med 1994; 331: 1314.
20. 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Safety 1994; 11: 259-283.
21. 2-agonists and their antagonists. Chest 1994; 106: 329-331
22. 2-agonist therapy: Vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995; 95: 641-651.
23. Vathenen AS, Higgins BG, Knox AJ, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; i: 554-558.
24. 2-agonists in asthma. N Engl J Med 1992; 327: 1204-1208.
25. Cockcroft DW, McPaarland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833-837.
26. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
27. van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CLA. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990; 86: 793-800.
28. Macklem PT. The clinical relevance of respiratory muscle research. Am Rev Respir Dis 1986; 134: 812-815.
29. Ullman A, Bergendal A, Linden A, et al. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea-pig trachea with or without epithelium. Allergy 1992; 47: 384-387.
30. Derom EY, Pauwels RA, Van der Straeten ME. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol 1992; 89: 811-815.
31. 2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993; 48: 1121-1124.
32. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-1239.
33. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956.
34. Sears MR. Long-acting β-agonists, tachyphylaxis and corticosteroids. Chest 1996; 109: 862-864.
35. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993; 306: 1034-1037.